Lincoln Pharmaceuticals Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹191 Cr +17.2% YoYSee revenue, profit and what management said. You are viewing Q1 FY26.
LP

Lincoln Pharmaceuticals Ltd

Q1 FY26Pharmaceuticals & Biotechnology

Lincoln Pharmaceuticals Q1 FY26 earnings call: Revenue & Margins

Q1 FY26 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹154Cr
+4.8% YoY
−8.3% QoQ
Net profit
₹28Cr
+16.7% YoY
+133.3% QoQ
Margin
15%
0 pp YoY
−1 pp QoQ

Based on Lincoln Pharmaceuticals Ltd's Q1 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹595
Market cap₹1.2K Cr
P/E12.6

The short version

EBITDA for the quarter: ₹9.19 crore, up 52.3% year-on-year - Operating margin: 20.3%, increased from 14.9% year-on-year - Profit After Tax (PAT): ₹5.95 crore, up 45.6% year-on-year

From Lincoln Pharmaceuticals Ltd's Q1 FY26 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

See what Lincoln Pharmaceuticals Ltd said on revenue & sales performance — free account, 30 seconds.

Profitability & Margins

See what Lincoln Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

See what Lincoln Pharmaceuticals Ltd said on capital expenditure plans — free account, 30 seconds.

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Lincoln Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Lincoln Pharmaceuticals Ltd said on order book & pipeline — free account, 30 seconds.

Lincoln Pharmaceuticals Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Lincoln Pharmaceuticals Ltd Q1 FY26 results — key figures

Lincoln Pharmaceuticals Ltd Q1 FY26 reported results vs Q1 FY25, ₹ crore
₹ CrQ1 FY26Q1 FY25YoYQ4 FY25QoQ
Revenue154147+4.8%168-8.3%
Operating profit (EBITDA)2423+4.3%27-11.1%
Operating margin15%15%0 pp16%-1 pp
Profit before tax3529+20.7%16+118.8%
Net profit (PAT)2824+16.7%12+133.3%
EPS (₹)13.8211.82+16.9%5.78+139.1%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹191 Cr, net profit ₹20 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • RPG Life Sciences (Q1 FY26)

    168.9 crores vs Rs. Key concall takeaways from RPG Life Sciences Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

  • SMS Pharmaceuticals (Q1 FY26)

    Q1FY26 revenue from operations: ₹196.05 crore . Key concall takeaways from SMS Pharmaceuticals Ltd's Q1 FY26 earnings call — and how it ranks against sector…

  • Morepen Laboratories (Q1 FY26)

    Crores)**: . Key concall takeaways from Morepen Laboratories Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

  • NGL Fine Chem (Q1 FY26)

    Q1FY26 Revenue from operations: ₹104.19 crores . Key concall takeaways from NGL Fine Chem Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Lincoln Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Lincoln Pharmaceuticals Ltd Q1 FY26 results?

EBITDA for the quarter: ₹9.19 crore, up 52.3% year-on-year - Operating margin: 20.3%, increased from 14.9% year-on-year - Profit After Tax (PAT): ₹5.95 crore, up 45.6% year-on-year

What is Lincoln Pharmaceuticals Ltd share price analysis?

Lincoln Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 12.6 with a market cap of ₹1,212 Cr. Investors should review the full earnings analysis for detailed insights.

Keep Lincoln Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.